By Josh Beckerman
Renovaro shares declined after the company said it received an email from Predictive Oncology terminating an agreement to be sold to Renovaro.
The stock fell 16% to 39 cents in the regular session Friday. It was up 5% to 41 cents after hours.
"Renovaro's position is that POI must comply with the binding obligations thereunder and enter into an exclusive license agreement as required in each of the binding agreements," the company said. It believes Predictive Oncology is in breach of the binding agreements.
A representative for Predictive Oncology didn't immediately reply to a request for comment.
Renovaro focuses on diagnostics, drug discovery and genetically enhanced cancer therapies.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 04, 2025 18:45 ET (22:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.